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Background: Irritable bowel syndrome (IBS) is a common gastrointestinal functional disorder with no effective
therapy. Traditional Chinese medicine (TCM) is one of the most common complementary therapies in China. We
designed this study to evaluate the efficacy and safety of Shun-Qi-Tong-Xie Granule (SQTX Granule), a TCM
treatment, in patients with IBS with diarrhea (IBS-D).
Methods/Design: A randomised, double-blinded, placebo-controlled, multi-centre, superiority clinical trial to
evaluate the efficacy and safety of SQTX Granule is proposed. Eligible patients (Rome III) with IBD-S will be randomly
assigned into SQTX Granule group and the placebo group. Patients will receive a 28-day treatment and a 2-month
follow-up. The primary outcome measures include the scores of IBS-quality of life (IBS-QOL) rating scale and
IBS-symptom severity scale (IBS-SSS) rating scale. The secondary outcome measures include the improvement of
symptom scores, and the duration of abdominal pain and diarrhea.
Discussion: According to TCM theory, SQTX Granule has a regulating effect on abdominal pain, diarrhea and the
syndrome of liver-spleen disharmony, which is similar to the symptoms of IBS-D. This study will provide objective
evidence to evaluate the efficiency and safety of SQTX Granule in IBS-D treatment.
Trial registration: ChiCTR-TRC-14004241.
Date of registration: 9 February 2014.
Keywords: Irritable bowel syndrome, Diarrhea, Traditional Chinese medicine, Shun-Qi-Tong-Xie Granule, Randomised
controlled trialBackground
IBS refers to a clinical syndrome that presents as a com-
mon chronic gastrointestinal disorder. Patients suffer
from abdominal pain or discomfort, bloating, and altered
bowel habit, which vary in both degree and frequency,
from slight to severe and from recurrent to persistent,
respectively [1]. The disease is one of the most common
functional gastrointestinal (GI) disorders with a reported
prevalence of approximately 5 to 20% worldwide [1-3].
IBS is more commonly diagnosed in women than in
men, and in patients younger than 50 years [1,4,5]. IBS
considerably reduces patients’ quality of life, interfering* Correspondence: jiajia818@163.com
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unless otherwise stated.with their working ability and social activity, and it also
results in a significant economic burden through de-
creased work productivity and increased healthcare costs
[6]. With the accelerated pace of life and changes in diet
in recent years, neurological, psychiatric and infectious
factors have caused an upward trend in the incidence of
IBS [7-9]. No biomarkers have been found for IBS diag-
nosis [10], so IBS is diagnosed by assessing symptoms,
according to the Rome III criteria [11,12]. According to
these criteria, four subtypes of IBS were recognised: IBS
with constipation (IBS-C), IBS-D, mixed IBS (IBS-M),
and unsubtyped IBS (IBS-U). Each IBS patient could
switch from one subgroup to another over time. Current
medication approaches for IBS are based on symptom
reduction, yet many patients remain undertreated;
meanwhile, many medication approaches are associatedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Wang et al. Trials 2014, 15:273 Page 2 of 8
http://www.trialsjournal.com/content/15/1/273with side effects that result in less benefit to the patient,
particularly in treatment for long-term relief of abdom-
inal pain or discomfort.
Due to unsatisfactory treatment effectiveness, the
search for and use of complementary and alternative
medicines (CAM) has increased during the past several
years around the world [13-15]. Studies indicate an im-
provement both in the abdominal complaints and the
quality of life in IBS patients adopting CAM treatment,
which includes dietary supplements, TCM, acupuncture,
moxibustion and botanicals [13-16]. TCM is one of the
most common CAMs used in China, and it has an over
5,000-year history of applications for various diseases,
including IBS-D [17]. According to TCM theory, one of
the most important principles of diagnosis and treat-
ment is symptom differentiation, which is based on four
diagnostic methods (inspection, listening and smelling,
inquiry and palpation) to collect clinical manifestations,
including symptoms and TCM signs.
In IBS-D, the most common symptom type is liver-
spleen disharmony, and it is primarily characterised by ab-
dominal pain/discomfort, diarrhea, chest/flank/abdominal
distension, belching, frequent sighing and emotion-related
symptoms. According to the basic principles of TCM,
IBS-D with liver-spleen disharmony is treated by relieving
stagnation of liver qi, as well as improving the transporta-
tion function of the spleen. First recorded in the TCM
classic ‘Jingyue's Complete Works’, Tong-Xie-Yao-Fang
(TXYF) decoction has been applied since the Ming Dyn-
asty (16th century) to cure abdominal pain with diarrhea
(liver-spleen disharmony). Modified from TXYF decoc-
tion, Shun-Qi-Tong-Xie (SQTX) Granule treats abdominal
pain, distention and diarrhea in patients suffering from
IBS-D (liver-spleen disharmony), and it is formulated with
the Chinese herbs listed in Table 1, which have all been
approved by the China Food and Drug Administration
(CFDA) [18]. In preclinical trials and toxicological studies,
no evidence of toxic effects has been found with SQTX
Granule. Pharmacologic experiments showed that it has
the effects of inducing spasmolysis, analgesia and reducing
diarrhea in rats with diarrhea caused by stress. Phase II
clinical trials also showed that SQTX Granule can im-
prove symptoms of abdominal pain/discomfort and theTable 1 Standard formulation of Shun-Qi-Tong-Xie (SQTX)
Granule
Pinyin name Latin name
Baishao Paeonia lactiflora Pall.
Baizhu Atractylodes macrocephala Koidz.
Xiebai Allium macrostemon Bunge.
Cheqianzi Hegba Plantaginis Asiaticae
Foshou Citrus medica L. var. sarcodactylis Swingle
Boheyou Oleum Mentha haplocalyx Briq.degree and frequency of diarrhea for patients with IBS-D
(liver-spleen disharmony).
Chinese herbs have been used for a long time with good
effects and few adverse events; however, a randomised,
double-blind, placebo-controlled trial is still necessary to
prove the efficacy and safety of any medication. As a phase
III clinical trial, the objective of this study is to evaluate
the efficacy and safety of SQTX Granule with a placebo in
patients with IBS-D (liver-spleen disharmony). The results
of this study will provide evidence regarding the value of
SQTX Granule as an intervention for IBS-D.
Methods/design
Design
This study is designed as a randomised, double-blinded,
placebo-controlled, multi-centre, superiority clinical trial.
This study is a phase III clinical trial and has been
authorised by the CFDA (Approval Number 2007 L02218).
In addition, the study is registered with the Chinese Clinical
Trial Registry (ChiCTR-TRC-14004241). The study is finan-
cially supported by Shaanxi Bosen Biological Pharmaceut-
ical Group Co. Ltd, Xi’an, China. This funding source is
providing test drugs, but it had no role in the design of
this study and does not have any responsibility for ana-
lyses, interpretation of the data or the decision to submit
results. Trained research nurses introduce the trial to pa-
tients, and give them information sheets and consent
forms. All patients have to give their written informed
consent prior to enrolment. The study’s flow chart is
shown in Figure 1.
Ethics
The trial protocol is conducted in accordance with the
Good Clinical Practice Guidelines and the Declaration of
Helsinki (2008) [19]. Ethics approval has been obtained
from the Clinical Trials and Biomedical Ethics Commit-
tee of West China Hospital of Sichuan University (Num-
ber TCM-2013-01). Written informed consent will be
obtained from each patient.
Recruitment
A total of 440 Chinese patients who fulfill the screening
criteria will be recruited at eight large comprehensive
hospitals in China: 1) West China Hospital of Sichuan
University, 2) Affiliated Hospital of Chengdu University
of TCM, 3) The First Affiliated Hospital of Heilongjiang
University Of Chinese Medicine, 4) Affiliated Hospital of
Jiangxi University of TCM, 5) Shanxi Provincial Hospital
of TCM, 6) The First Affiliated Hospital of Guangxi
University of Chinese Medicine, 7) Gansu Provincial
Hospital of TCM and 8) Affiliated Hospital of Changchun
University of Chinese Medicine. Each centre will recruit
55 patients through posters in local hospitals.
Figure 1 Study flow chart. The flow chart of enrolment, allocation, intervention and assessment.
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According to the results of Phase II clinical trial, the re-
sponse rates of SQTX Granule and placebo were 0.51
and 0.33, respectively. Assuming the response rates for
TCM and placebo were 0.5 and 0.35, the sample size
was calculated under the setting of alpha = 0.05 and
beta = 0.80. Taking into account a drop-out of 15%, the
sample size needs to be 150 cases for each group. A
total of 440 patients will be recruited in this trial, in-
cluding 330 cases for the SQTX Granule group and 110
cases for the placebo group in a 3:1 ratio.
Randomisation
With a stratified block randomisation method, a 440-
case randomisation arrangement was carried out by an
independent statistician according to the sequence gen-
erated with SAS software; this lists a serial number from
001 to 440 corresponding to consecutive allocation (with
a randomisation scheme). Each centre receives consecu-
tively coded drugs. All of the drugs provided by the
pharmaceutical company will be numbered with a label
according to the randomisation schedule.
Blinding
This trial is a double-blind trial. The first level is for the
case number corresponding to groups (group A, group
B), and the second level is for the group corresponding
to intervention (the test and placebo groups). The num-
bers are kept in opaque sealed envelopes. The double
levels of blinding are sealed separately, and given to the
leader and the sponsor of the clinical research. Emer-
gency letters are sent to each of the centres, saved with
the test drug, and properly preserved until the end of
the trial. Treatment assignments will not be revealedand are blinded to the patients and investigators (includ-
ing statisticians) until the entire study is completed.
Code-breaking should only occur with the permission of
the research centre leader in exceptional circumstances
when serious adverse events happen and knowledge of
the actual treatment is absolutely essential for further
management of the patient, and a report should be sub-
mitted to the leader of the trial within 24 hours. For the
first level of unblinding, before statistical analysis, the blind
code will be disclosed to group A and group B. For the sec-
ond level of unblinding, group A and group B will be dis-
closed to the test placebo groups in a summary meeting.
Western medicine diagnostic criteria for IBS-D
Diagnosis of IBS-D is established according to the Rome
III criteria [11,12], mode listed in Table 2.
Diagnostic criteria*:
Recurrent abdominal pain or discomfort** at least
three days/month in the last three months associated
with two or more of the following:
1. Improvement with defecation
2. Onset associated with a change in frequency of stool
3. Onset associated with a change in form (appearance)
of stool
*Criteria fulfilled for the last three months with symp-
tom onset at least three months prior to diagnosis
**‘Discomfort’ means an uncomfortable sensation not
described as pain.
In pathophysiology research and clinical trials, a pain/
discomfort frequency of at least two days a week during
the screening evaluation is recommended for subject
eligibility.
Table 2 Mode of irritable bowel syndrome (IBS)
Question Score
A) In the last 3 months, how often
did you have hard or lumpy stools?
0 Never or rarely
1 Sometimes
2 Often
3 Most of the time
4 Always
B) In the last 3 months, how often did
you have loose, mushy or watery stools?
0 Never or rarely
1 Sometimes
2 Often
3 Most of the time
4 Always
Mode Definition
IBS-C A > 0 and B = 0
IBS-D A = 0 and B > 0
IBS-M A > 0 and B > 0
IBS-U A = 0 and B = 0
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The TCM diagnosis of liver-spleen disharmony and diar-
rhea syndrome is based on the Guidelines for Clinical
Research of New Chinese Medicine [20].
For diagnosis with liver-spleen disharmony and diarrhea
syndrome, patients will have both of the primary and at
least two of the secondary symptoms listed in Table 3, as
well as the TCM signs for the tongue and pulse.
Inclusion criteria
 Diagnosis of IBS-D according to Western medicine
 Diagnosis of liver-spleen disharmony and diarrhea
syndrome according to TCM
 Aged between 18 and 65 years old
 Able to understand and sign a written informed consent
Exclusion criteria
 Diagnosis of IBS-C, IBS-M or IBS-U according to
Western medicineTable 3 Traditional Chinese medicine (TCM) diagnostic
criteria
Category Symptoms and signs
Primary symptoms 1) Abdominal pain or discomfort, 2) Diarrhea
Secondary symptoms 1) Chest/flank or abdominal distension,
2) Diarrhea aggravation related to emotional
tension, depression or anger, 3) Belching,
4) Decreased appetite, 5) Frequent sighing,
6) Fatigue
TCM signs for the tongue Pink tongue, white/thick/greasy tongue coating
TCM signs for the pulse Wiry pulse A history of previous abdominal surgery
 Other organic diseases causing abdominal pain and
diarrhea
 History of usage of other medication for IBS-D
during the last week
 Patients taking any medication for other diseases
which would impact the trial
 Pregnant and lactating women
 Patients who have an allergic constitution or are
allergic to the trial medicine
 Patients with serious primary diseases of the heart,
liver, kidney, blood system or endocrine system, and
patients with tumours or AIDS
 Mentally or legally disabled patients
Other criteria
Withdrawal of participants:
 Patients are determined as requiring withdrawal
based on disease progression, allergic reactions,
serious adverse events, or poor efficacy
 Serious complications
 Unblinding individuals for any reasons
 Voluntarily quitting
 Unable to complete the scheduled follow-up
Reasons for withdrawing patients would be noted in
Case Report Forms (CRFs), and the last data would be
included in data analysis.
Note: 1) Patients cured in a course of treatment are not
regarded as cases for withdrawal.
2) Patients withdrawn due to poor efficacy after a half
course of treatment (14 days) are regarded as not
recovered but not withdrawn, and they would be




 Using forbidden drugs or treatments in the course
of the trial
 Taking no medication during the trial
 No evaluable records after medication
The whole study will be terminated if any of the
following occurs
 Poor curative effect is found during the study
 Significant deviation from the protocol
 Flawed protocol
 The sponsors decide to terminate the trial due to
management or funding problems
Wang et al. Trials 2014, 15:273 Page 5 of 8
http://www.trialsjournal.com/content/15/1/273 At the decision of the pharmaceutical supervisory
and administrative departmentConcomitant treatments and forbidden drugs
Usage of any other Western medication or Chinese med-
icines that have similar effects to SQTX Granule, or may
affect the analysis of the final results, is strictly prohib-
ited. Medications used to control other conditions of the
participants, such as hypertensive or diabetic medica-
tions, are allowed. The dosage, duration and name of
any concomitant treatment or medication must be re-
corded carefully in the CRFs.Figure 2 Study schedule for patients. After the enrolment and allocation
follow-up of eight weeks. The time-points of assessment are shown in theTest drugs
The test drugs are SQTX Granule and placebo, which
are indistinguishable from the actual medication. The
placebo has the same shape, size, taste, colour, package
and Lot number.Intervention
Patients are administered SQTX Granule or placebo in
one bag (0.5 g per bag) dissolved in warm water three
times daily for 28 days. The follow-up visits last for one
week after the treatment. The measurements that need
to be performed at each visit are listed in Figure 2., participants will receive the administration for four weeks and a
schedule.
Wang et al. Trials 2014, 15:273 Page 6 of 8
http://www.trialsjournal.com/content/15/1/273Outcome assessment
Primary outcome
 Scores of IBS-quality of life rating scale (IBS-QOL)
rating scale [21]
 Scores of IBS-symptom severity scale (IBS-SSS) rat-
ing scale [22]
Secondary outcome
 The symptom score system is introduced to quantify
the degree of abdominal pain, diarrhea, stool
consistency and other concomitant symptoms as
shown in Figure 3, following the Guidelines for
Clinical Research of New Chinese Medicine [20].
 The treatment efficacy evaluation system is
introduced to evaluate the improvement of symptoms
using the percentage of symptom score reduction
(PSSR). The PSSR for a patient after treatment is
calculated according to the following formula:
PSSR ¼ SymptomscoreatDay 0‐SymptomscoreatDay 28
SymptomscoreatDay 0
 
100%Figure 3 Symptom score system. As a secondary outcome, a Traditional
this protocol.Full recovery: PSSR ≥ 90%, Good recovery: 90% > PSSR ≥
70%, Modest recovery: 70% > PSSR ≥ 30%, No recovery:
PSSR < 30%.
 Decreasing and disappearing time of abdominal pain
and diarrhea:ChineDecreasing time= (The day pain/diarrhea decrease) - Day 1
Disappearing time = (The day pain/diarrhea
disappear) - Day 1Safety outcome
A routine blood test, routine urine test, routine stool test,
faecal occult blood test, urine pregnancy test (women
only), liver function test, renal function test and an elec-
trocardiogram are administered for safety outcomes,
which are monitored both before and after treatment.Data management
After review by clinical inspectors, completed CRFs will
be sent to a specified statistics centre, and data entry
and management is completed by two individual data
administrators to ensure the accuracy of the data. To en-
sure the database is created correctly after blind review,
data will be locked by the clinical research leader, these medicine (TCM) symptom score system is introduced into
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are allowed to the locked data.
Adverse events
Adverse events will be recorded and graded in detail
throughout the study. When a severe adverse event oc-
curs, participants will be provided with every necessary
treatment, and the event must be reported to the leader
of the trial, ethics committees, sponsors and CFDA
within 24 hours.
Data analysis
Statistical analysis will be conducted based on an intention-
to-treat (ITT) principle. All subjects who were treated with
at least one dose of the study drug and had at least one
clinical observation after starting the treatment comprise
FAS. All treated subjects without any major protocol devia-
tions comprise PPS. The statistical analysis will be per-
formed using the SAS 8.1 software (SAS, Cary, NC, USA).
The statistical significance is defined as a two-sided P-value
of < 0.05. Baseline differences among the groups will be
assessed with the use of the one-factor analysis of variance
or the Mann-Whitney U-test for measurement data and
the χ2 test or the Wilcoxon test for enumeration data. For
categorical variables, a χ2 test or Fisher’s exact test will be
used. The changes from baseline to endpoint of treatment
in scores will be assessed with the use of a paired t-test for
measurement data and a signed rank test for enumeration
data. Comparisons between groups will be conducted by
using an analysis of variance (ANOVA) and a rank test.
Discussion
Characterised by continuous or intermittent abdominal
pain, bloating, changes of bowel habits or stool consistency,
IBS is a disease lacking any changes of gastrointestinal
structure and biochemical abnormalities. Moreover, greatly
impacting the function of the gut, psychological stress
plays a fairly important role in inducing, aggravating and
perpetuating the symptoms of IBS; thus, a portion of IBS
patients exhibit mental disorders, mainly anxiety and
depression [23-26]. No evidence of any pathological
change is found. Current Western medicine provides lim-
ited symptomatic relief to IBS patients through pharmaco-
logical treatment; however, TCM has a long history
spanning thousands of years, dealing with abdominal pain
and diarrhea. In recent years, a group of studies con-
firmed the efficiency of TCM treatment on IBS [27-29].
As the most common type of IBS, IBS-D is charac-
terised by abdominal pain/discomfort and diarrhea,
mainly accompanied with emotional instability, which
is the exact indication of SQTX Granule in our study.
Pharmacological and toxicological research with SQTX
Granule demonstrated the efficacy and safety in preclin-
ical trials, respectively, and phase II clinical trials alsoindicate the improvement of symptoms without significant
adverse events. A randomised, multi-centre, double-blind,
placebo-controlled, superiority, phase III clinical trial will
be helpful for further clarification of these results.
Trial status
At the time of manuscript submission, patient recruitment
for the trial is on-going.
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